Orexigen reports progress with FDA on faster path to Contrave NDA resubmission

Orexigen Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced progress with the United States Food and Drug Administration (FDA) on a faster path to resubmission of the Contrave (naltrexone SR / bupropion SR) New Drug Application (NDA).

Read more...
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

8 Ways to Trick Yourself Thin

8 Ways to Trick Yourself Thin An article from By Chris Freytag The formula for weight loss may be simple-take in fewer calories ...